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DISCUSSION FOLLOWING THE REMARKS OF
MS. COFFIELD AND MR. FRECHETTE
QUESTION, PROFESSOR KING: I had a question for both of you. The
real issue here is whether these health and safety measures are disguised
barriers to trade, at least in the Canada/U.S. context. Do you think that some
joint testing relationships are valuable?
Also, if you have some goods, you want to ship them to Canada, and you
want free reign, is there any advanced warning operation that you could use?
What steps do you take to avoid this type of difficulty? I think that we will
see more of this in the future. We have seen it in Europe where it is
sometimes a disguised trade barrier. Shirley, would you start, and then Serge,
would you tackle it afterwards?
ANSWER, MS. COFFIELD: We do some joint testing already. I have
had an experience, for example, with a client association that was concerned
about the E.U. residue testing requirements, which involved the hormone
ban. They are letting in meat that is not hormone-treated. There were some
slippages in that system. The E.U. found that meat certified as non-hormone
treated in fact had some hormones in it. So the E.U. was going to restrict all
red meat of any kind from the United States just a few months ago. The
United States did not have testing facilities that met E.U. standards. So the
meat has been sent to a lab in Canada for the last for testing to meet the E.U.
certification requirements. The E.U. came out and actually audited a
Canadian facility in order to certify that it met their requirements for the U.S.
exported meat. So we already, in certain areas, are depending upon each
other in these areas of common concern.
With respect to pesticides and the United States, there are procedures for
fairly rapid certifications. I have experienced a situation where a product was
being sent in as a preservative for Post Cereal Company, but it also could
have been used in a veterinarian application. The exporter did not know that
and there was great concern. We were able to go and quickly get that
regularized so it could come in. There is far more willingness between these
two governments not to use these regulations as barriers to trade. The barriers
to trade that come up inadvertently have to do with cumbersome procedure in
the system. In the United States, there are several agencies involved: the
Environmental Protection Agency (EPA), the United States Department of
Agriculture (USDA), three or four agencies in the Food and Drug
Administration (FDA), a Center for Disease Control, and the National
Institute of Health (NIH). All of these agencies have a role in setting the
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policies and implementing and enforcing what comes into the United States.
Many of the problems are logistical problems. They are administrative
problems that are not deliberate.
That is not the case with some other countries. In South America, for
example. They are trying to get even, so to speak, for all the years we did
not let anything from their county into the United States. Argentina is now
off the list for foot and mouth disease, and parts of Mexico for African swine
fever. There is a newfound zealousness in those governments to make sure
anything coming from the United States or Canada meet certain
requirements, which may seem to us to be overly protectionist. I give them
the benefit of the doubt. I hope that over a period of time governments will
really make a concerted effort not to use this as a trade restriction. Call it and
deal with it, but do not require a certificate that is three pages long and
requires veterinarians in other countries to certify to exotic diseases that the
United States and Canada, who have huge administrative systems, are not
able to cope with.
ANSWER, MR. FRECHETTE: On the issue of joint testing, I cannot talk
with as much authority as Shirley because I have never run into any issues
there. It is apparent that both the administrations in Canada and the United
States are trying to work toward finding ways to ensure that there are no
barriers. Joint testing is an obvious solution that could be used more than it is
used. Joint testing implies an agreement on the procedures that will be used,
and that will have acceptable results. Having joint testing may be a useful
tool, but that very much depends on what the standards will be with respect
to the particular good being tested and the tests. But I think, theoretically, I
am in full agreement with Shirley.
QUESTION, MR. NORMAN: I want to raise a question that has not been
addressed, or an issue that has not been raised by either of you, and that is the
ownership of genetically enhanced products. The concern, as has been
expressed to me by people who know a lot more about this than I do, is that
we appear to be heading toward a situation where we may have four, five, or
six large, multi-national corporations owning a large proportion of the
world's genetic material because they developed it, and they own the
technology and product rights. I would like to hear your views. This is,
perhaps, an intellectual property issue, or maybe even a competition policy
issue. I would be interested in whatever views you might have and ways to
deal with it.
ANSWER, MS. COFFIELD: I talked earlier very briefly about
bioethicists, and this is one of the real concerns about how you deal with
genetically modified foods (GMOs). Many companies have agreed to release
their patents and freely make them available in developing countries. For
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example, for the use of genetically modified rice, particularly, where vitamin
A and/or iron can be added to the rice, the results could be a huge help in
eradicating certain diseases or deficiencies; such as blindness in some
developing countries. Whether the companies did this because of a cleverly
constructed plan to make everybody think they are good people or not, I do
not really care, but it is being done. There will be more pressure for that in
the future.
When you are talking about commercial products, such as Round Up
resistant corn,' whether or not the competitive advantage gained by holding
the patent goes into intellectual property issues or not, both countries
recognize that investments should be rewarded and that investors should be
able to recover their investment. I know there have been differing views
between the United States and Canada for a number of years as to how long a
patent can be held. The question is how you do that, for how long, and to
what extent these products are going to be generally available.
I think it is an issue. I would not go to the extreme position and say that
the multi-nationals will control the world in six years because they hold these
patents to their chests. I do not think it is going to be allowed.
There will be mechanisms allowinf them to recover their investments and
make a profit. If these are as good as they say they are, they ought to be able
to do that and be very happy, particularly because, in certain instances, they
are going to be releasing these patents for use in developing countries.
QUESTION, MR. DELAY: Henry, will you admit that the food at this
conference has been genetically engineered?
ANSWER, MS. COFFIELD: Yes, it has. I would expect eighty percent of
what you eat contains products that have come from genetically modified
crops.
QUESTION, MR. DELAY: In order to prevent legal problems before
they become legal problems, is there an advantage to having some form of
standing panel, broadly composed of geneticists, biologists, maybe even
some of these Greenpeace people or physicians who would screen some of
the more controversial biogenetically engineered products and run them
through some discussion or analysis; maybe not as thorough as an FDA?
ANSWER, MR. FRECHETTE: There is an advantage in everything you
can find to solve the problem before it hits the dispute settlement stage.
Countries using the dispute settlement process could decide that before they
trigger the system past the consultation stage they should consult with
I Round-Up, manufactured by Monsanto, is the largest selling herbicide in the world.
Round-Up ready crops are engineered to withstand increased applications of the herbicide. See
Round-Up ready Corn Under Attack in California (visited Aug. 3, 2000)
<http://www.infoshop.orgnews4/cacorn.html>.
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experts to find out what the status of science is on a particular issue. They
could solve the issue there if they are willing to make the policy decisions
required in order to settle the matter at that point. The problem is too often
that governments get put in positions where they cannot backtrack. They
have no choice but to go to a panel and test to find out what the view will be
from a reasonable person's point of view.
One of the reasons you end up in this situation is that you often have one
part of the literature saying one thing, and another part of the literature
saying pretty much the same thing, but with a nuance. The reason why you
end up with a dispute is that a government, because it is pushed by an
industry will give a certain meaning to that nuance which creates a dispute.
Whether you do it before or after, ultimately the practice has been, at
least in the WTO context to hear from experts. Asbestos is a good example.
The problem is, when you have a panel doing that you will have a decision
that will try to solve the dispute, instead of having the parties trying to solve
the dispute in advance.
There are obvious advantages in trying to solve the matter ahead of time.
It inevitably depends on the government's willingness to agree on what the
solution should be, which is not obvious.
COMMENT, MS. COFFIELD: Even before you get to that stage there
needs to be better agreement on protocols for testing genetically modified
organisms. That is how you determine that they are safe. There are ways of
doing this and there are protocols in use in the United States and Canada,
which are heavy users of GMOs. If there could be an agreement that would
be a first step. What we need is an agreement on how to determine that
something is safe to put out into the general environment. That is a basic
question that we have not addressed here. Some people are saying it is never
safe. That is not a trade issue-it is an ethical issue.
Once we get past that, it is a question of whether or not we can agree to
the necessary protocols. Then perhaps we can get into panels looking at how
the protocols are used. In other words, this is not a one step issue. It is going
to take many steps before this is going to be able to be resolved in a way that
is acceptable to the majority of entities who use GMOs. We are never going
to have 100% agreement on this, as we do not have 100% on anything else.
QUESTION, MR. URLICH: The Biosafety Protocol recently negotiated
in Montreal, contains provisions for the application of the precautionary
principle. The question I have is two-fold. First, does the establishment of the
precautionary principle and the protocol establish it as a customary principle
of international law, thereby complicating future decisions in various
disputes? Second, does it provide sort of a trampoline or create political
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momentum for integrating the precautionary principle into codex or maybe
some other agreements?
ANSWER, MS. COFFIELD: That is a very good question. The
precautionary principle, you know, is an E.U. construct, and it was heavily
opposed by the Miami Group, which included Canada. Actually, Canada was
a surrogate for the United States in these negotiations because, as you heard,
the United States is not a signatory to the Convention on Biodiversity, but it
was an energetic participant, if I can put it that way.
As to the question you raised regarding whether or not this will become
customary international law, I hope that there will be some discussion. My
own view right now is that I would like to argue that it would not be; that it is
really a subsidiary mechanism by which decisions are made, and not a
substantive rule itself. But that just now came off of the top of my head, and
so it is not something I have looked at. I hope I do not have to look at it.
This whole precautionary principle can be and will be a trampoline for
countries to argue that, as far as they are concerned, their people do not want
it. I will have to say with respect to the E.U., ten years ago they did not mind
having it at all. As you may know, they did not mind having growth
hormones, for example. There is a very active black market in growth
hormones in the E.U. There are a lot of growth hormones being used now in
the E.U. If the E.U. had not made this an issue, their public would not have
created that monster. Now they have to live with the monster. There are a
number of people in the E.U. in official positions who wish they had not
done that. This question of whether this monster can be created many times
over in GMOs is a very real concern.
QUESTION, PROFESSOR KING: Good, well, do you have any
comments on the monster?
COMMENT, MR. FRECHETTE: I have just a very short comment on
the question that Bill raised. Some people are actually saying that it may be
the first step for the E.U.; that you will see the E.U. coming back with this
idea and trying to develop it in other fora as well. Why? Because they want
to build the concept that there is greater acceptance to this principle so that
they can bring it back later on in the context of the SPS where it refers to
international standards. So, in the context of a dispute, they could point out
the existence of international standards, something that is generally accepted.
Therefore, say our domestic measure is challenged and it is basically based
on that standard. That is a theory that certain people say may be what is
starting to happen. Whether or not it does happen depends on many legal
criteria that have been developed in public international law over the past
hundred years. When does something become a customary international rule?
COMMENT, PROFESSOR KING: That is a tough question.
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QUESTION, MR. COTE: What do you do in the case where a country
decides in one month, two, or three months to impose labeling standards, and
what do you do for the countries who are hit by that? Does the SPS
Agreement under the WTO deal with that or does the NAFTA? Which
agreement will be used?
ANSWER, MS. COFFIELD: The question was whether a labeling
requirement would be actionable under the WTO or the NAFTA.
It would be actionable under the TBT agreement in the WTO, which
covers labeling, rather than under than the SPS. I am expansionist in my view
of what can be brought before the WTO, and I would have no compunction
whatsoever in bringing a case or encouraging my government to bring a case
if I could demonstrate both a method for choosing the rule and the impact of
the rule, in fact, if it impaired my benefits. This sleep aid has a very long
exposition on the Japanese rule on the GMO labeling, which they have now
put into place. After you read that, you will see how very complicated it is. It
goes through everybody right down the line through the United States and
Japan.
At the end of the day, the United States and Canada will say they can live
with that. Why can they live with it? Because they allow a five percent error
rule; up to five percent can be not certified as free of GMO. What they are
saying is they cannot meet the zero tolerance, because they cannot ever tell if
there may be some odd mingling or mixing of a small percentage.
So even though it looked terrible to me, I am not the grain elevator
operator. They said they can keep that paper trail so long as it is not a zero
tolerance. In terms of labeling for GMOs, even though the United States is
not willing to admit it they are going to accept GMO labeling so long as it is
reasonable.
Once again the issue is, if it is safe to be out there then it should be out
there. Once again, labeling comes down to an ethical question. If you do not
want anything at all, why even allow it? If you are going to label it, let the
consumer decide. If there is up to five percent, if they want to go buy
something organic, let them do it. Those are the two kinds of views.
COMMENT, PROFESSOR KING: Shirley, that sleep aid is a take home
from the conference. It is something to remember Shirley by, from the
Canadian Food and Agriculture Department.
COMMENT, MR. NORMAN: I just wanted to make one comment on the
precautionary principle, and that is to point out that it is already in the WTO
Agreement on Sanitary Measures, but it is subject to constraints. There has to
be some scientific evidence that there is a risk that needs to be dealt with.
You can take a precautionary action against it, but you then have the
obligation to undertake further scientific research to get to the bottom of the
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problem and try to find the least restrictive way of dealing with it. So, the
principle is already there, subject to constraints.
COMMENT, MS. COFFIELD: A diverse discussion.
COMMENT, PROFESSOR KING: She says a diverse discussion, which
is very good. Thank you very much, Shirley and Serge.

